Investors

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient´s dendritic cells to activate an immune response specific to the patient´s disease. Argos´ most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.


Stock Quote

NASDAQ: ARGS
4.70
+ 0.25 (+5.62%)

Day High:
4.75

Day Low:
4.32

Volume:
50,583

4:00 PM ET on Dec 2, 2016
Delayed at least 20 minutes.